ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Recruiting · NCT07531745 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT07531745 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ionis Pharmaceuticals, Inc. | 22 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University Health Systems | Durham | United States | 1 |
| Le Bonheur Children's Hospital | Memphis | United States | 23 |
| Mayo Clinic | Rochester | United States | 664 |
| McGill University Health Center - Research Institute | Montreal | Canada | 1 |
| Seattle Children's Hospital | Seattle | United States | 281 |
| University of Michigan Health System | Ann Arbor | United States | 38 |